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Abstract
Background: Cardiovascular (CV) events are prevalent and expensive worldwide both in terms of direct medical
costs at the time of the event and follow-up healthcare after the event. This study aims to determine initial and
follow-up costs for cardiovascular (CV) events in US managed care enrollees and to compare to healthcare costs
for matched patients without CV events.
Methods: A 5.5-year retrospective matched cohort analysis of claims records for adult enrollees in ~90 US health
plans. Patients hospitalized for first CV event were identified from a database containing a representative sample of
the commercially-insured US population. The CV-event group (n = 29,688) was matched to a control group with
similar demographics but no claims for CV-related events. Endpoints were total direct medical costs for inpatient
and outpatient services and pharmacy (paid insurance amount).
Results: Overall, mean initial inpatient costs were US dollars ($) 16,981 per case (standard deviation [SD] =
$20,474), ranging from $6,699 for a transient ischemic attack (mean length of stay [LOS] = 3.7 days) to $56,024 for
a coronary artery bypass graft (CABG) (mean LOS = 9.2 days). Overall mean health-care cost during 1-year follow-
up was $16,582 (SD = $34,425), an excess of $13,792 over the mean cost of matched controls. This difference in
average costs between CV-event and matched-control subjects was $20,862 and $26,014 after two and three years
of follow-up. Mean overall inpatient costs for second events were similar to those for first events ($17,705/case; SD
= $22,703). The multivariable regression model adjusting for demographic and clinical characteristics indicated that
the presence of a CV event was positively associated with total follow-up costs (P < 0.0001).
Conclusions: Initial hospitalization and follow-up costs vary widely by type of CV event. The 1-year follow-up costs
for CV events were almost as high as the initial hospitalization costs, but much higher for 2- and 3-year follow-up.
Background
Cardiovascular (CV) events are prevalent and expensive
worldwide both in terms of direct medical costs at the
time of the event and follow-up healthcare after the
event. In 2006, the average cost at discharge for a Medi-
care beneficiary with a principal diagnosis of CV disease
(CVD) was $10,201 [1]. Continuing improvements in
medical care make contemporary assessments of incre-
mental CVD costs relevant and necessary for up-to-date
economic analyses. In addition, it is important that health
economic analyses consider the costs of specific CV
events in addition to a broad assessment of CVD.
Given the lack of up-to-date cost estimates for specific
CV events in the literature, we performed a retrospective,
matched cohort analysis of transactional billing (claims)
records to determine the cost of various specific CV
events. This study assessed the differences in total direct
medical costs for those with and without CV events while
controlling for potential confounders and underlying dif-
ferences that may exist among study groups as a means to
assess the incremental cost of CV events over average
health care costs. This study also examined cost differ-
ences between initial and subsequent CV events, as well as
differences in costs among patients with comorbidities of
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dyslipidemia (DYS).
The primary study objectives were to: determine over-
all costs of initial and subsequent CV events in patients
who have been hospitalized with a CV event; examine
costs of 1-, 2-, and 3-year follow-up care among all
patients with a CV event; and determine incremental
costs for CV events by comparing total costs of follow-
up care for patients with a CV event to similar patients
without a CV event.
Methods
Ethical Approval
Request to include details of the Institutional Review
Board that granted ethical approval or any requirements
for permission to use the data sets.
Data
Claims data were obtained from the IMS LifeLink: US
Health Plan Claims data base (formerly called the Phar-
Metrics Patient-Centric database), a nationally-represen-
tative longitudinal database containing fully adjudicated
medical and pharmaceutical claims for >50 million
unique patients participating in >90 commercial health
plans across the US. The database includes: inpatient
and outpatient diagnoses (as ICD-9-CM codes) and pro-
cedures (as CPT-4 and HCPCS codes), as well as retail
and mail order prescription records. CV events and pro-
cedures of interest and the corresponding codes are
shown in Table 1. Claims dates were available for all
services rendered. Additional data include: demographic
variables (age, gender, geographic region); product type
(e.g., Health Maintenance Organization [HMO], Pre-
ferred Provider Organization [PPO]); payer type (e.g.,
commercial, self-pay); provider specialty; and start and
stop dates for plan enrollment.
Study Period
The 5.5 year study period (including a 1-year identification
period) ranged from January 1, 2001 to June 30, 2006. All
patients with an index hospitalization for a CV event were
identified for analysis. For these patients, readmission
could occur during the follow-up period (up to June 30,
2006).
Study data were divided into 3 periods: identification,
pre-index, and follow-up. The identification period was
from January 1, 2001 through June 30, 2005. The first
hospitalization with relevant diagnosis or procedure
codes for a CV event during this period was designated
as that patient’s index event. If a hospitalization was asso-
ciated with >1 diagnosis or procedure code of interest,
the patient was included in each relevant event type; i.e.,
event types were not mutually exclusive. For example, if
a patient was admitted for MI and then underwent
C A B G ,t h a tp a t i e n tw o u l db ei n c l u d e di nb o t ht h eM I
and CABG categories. The date of first hospital discharge
with a diagnosis or procedure code of interest served as
the index date for that patient. The pre-index period was
defined as 1 year (12 months) prior to index hospitaliza-
tion admission date. Thus, beginning and ending dates of
the pre-index period varied among patients with the ear-
liest time at which the pre-index period could begin
being January 2000. Three follow-up periods were used
to create cohorts of patients with 12-, 24-, or 36-month
continuous enrollment after discharge from the index
hospitalization. Follow-up terminated at the end of the
patient’s enrollment period in the health plan or the
study end date (June 30, 2006). Patients who died were
included regardless of follow-up length. Because deaths
are not available in the claims data (due to privacy con-
cerns), a proxy algorithm was used to determine patient
deaths; in brief, patients were assumed to have died if
they had evidence of specific mortality-associated events
during the last month in which medical and pharmacy
Table 1 Codes for CV events, co-morbid conditions and
procedures
Diagnoses and Procedures Codes
Event ICD-9-CM
Heart failure with or without
CKD
398.91, 402.01, 402.11, 402.91,
404.01, 404.03, 404.11, 404.13,
404.91, 404.93, 428.xx
Myocardial infarction 410.xx, 412
Unstable angina and angina
pectoris
411.1, 413.x
Other ischemic heart disease 411.xx (except 411.1, 414.xx,
427.xx, V45.81, V45.82
Ischemic stroke 433.xx, 434.xx, 436, 437.0, 437.1,
438.xx, 997.02
TIAs and other CVAs 435.x
Peripheral vascular disease 440.0, 440.1, 440.2x, 443.xx
Co-morbid conditions ICD-9-CM
Hypertension 401.xx, 401.0, 401.1, 401.9, 402.
xx, 403.xx, 404.xx, 796.2
Dyslipidemia 272.xx
Diabetes mellitus 250.x0, 250.x2, 250.x
Procedure CPT-4
CABG 33503 - 33545
Coronary stenting 92980, 92981
Percutaneous transluminal
coronary angioplasty/
thrombectomy/atherectomy
92973, 92982, 92984, 92995,
92996
Percutaneous transluminal
pulmonary artery balloon
angioplasty
92997, 92998
Carotid endarterectomy 35301, 35390, 35901
CKD, chronic kidney disease; TIA, transient ischemic attack; CVA,
cerebrovascular accidents; CABG, coronary artery bypass graft.
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ning and ending dates of the follow-up period varied
among patients but could not extend beyond June 30,
2006.
Patients were tracked from admission for the index
hospitalization (or index date for non-event patients)
until the end of enrollment in the health plan or study
end date, whichever came first. All records relating to
the index hospitalization and subsequent follow-up from
the index date were extracted for analysis. Data pertain-
i n gt ot h ef i r s tC Ve v e n tr e a d m i s s i o ni nt h ef o l l o w - u p
period were also extracted for analyses.
Patient Selection
Subjects were stratified into two cohorts based on pre-
sence or absence of hospitalization for a CV event. The
CV-event group included all patients with a complete
hospitalization (admission and live discharge within the
identification period) containing relevant procedure or
primary diagnosis codes for a CV event during the identi-
fication period. A matched control group was used to
compare total follow-up costs between patients with and
without CV events.
Exclusion criteria for both CV-event and control
groups included: patient not continuously eligible for
drug and health benefits during their entire pre-index
and follow-up periods; health plan did not report days
supplied or quantity dispensed for medications; patient
<18 years of age at index; patient ≥65 years of age whose
insurance coverage was not “Medicare Risk” at any time
during study period (complete claims histories may not
be available for patients without Medicare Risk coverage
due to benefit coordination issues with other payers);
patient with evidence of pre-existing CVD (claims for
CV-related diagnoses or procedures in the pre-index per-
iod); or patient with index hospital stay of more than 27
days (99th percentile).
All records from the pre-index period, index event
(first hospitalization for the CV-event group and
matched index date for the non-event group), and fol-
low-up from the index date (to the end of June 2006)
were extracted. Records were linked using a unique
patient code. All medical, laboratory, and pharmacy
claims were compiled for the period January 1, 2000 to
June 30, 2006.
An index date was randomly assigned to control-pool
subjects during their health plan enrollment which
would guarantee collection of ≥1 year of pre- and post-
index data. Control-pool subjects were then matched
with CV-event subjects (on a 1:1 basis) by exact age,
gender, exact year of index date, and follow-up duration
(in 60-day bands). As the intent was to compare total
costs of CV-event follow-up to costs for an average
patient, and not to determine incremental costs of CV
events per se, patients were not matched on comorbid
conditions. A diagram of the study cohort identification
procedure is shown in Figure 1. In cases where a CV-
event subject had <12 months of follow-up data due to
death, they were matched with a control subject who
also had <12 months of follow-up. In these cases, the
index date for the CV-event subject was assigned to the
control subject. All unsuccessfully matched control-pool
subjects were excluded from the matched analyses.
Subjects with a CV event were also evaluated for evi-
dence of HTN, DYS, or DM during the pre-index period.
S u b s e t so fs u b j e c t sw i t h≥1 of these three comorbidities
of interest were created for analysis, with some subjects
included in >1 subset. Subjects with HTN, DYS, or DM
were identified by presence of relevant ICD-9 codes
(Table 1). Diabetes was also identified by presence of any
oral diabetes medication (with or without insulin).
For all CV-event subjects, we determined whether
there were any subsequent CV events after the index
hospitalization discharge. Subsequent events were deter-
mined by finding complete hospitalizations with relevant
diagnosis or procedure codes of interest during the fol-
low-up period. The number of subsequent events per
subject and total medical costs associated with the first
subsequent (ie. second) CV event were calculated.
Measures of Interest
Measures of interest for analysis included: subject demo-
graphic and clinical characteristics; number of subse-
quent CV events; total medical costs following index CV
event; direct medical costs associated with the index hos-
pitalization (total cost and LOS); direct medical costs of
hospitalization associated with second CV event hospita-
lization (total cost and LOS); total all-cause follow-up
medical costs after index hospitalization discharge; total
CV-related follow-up costs after index hospitalization
discharge (ie. claims for outpatient CV medications or
CV-related procedures).
Total medical costs included all healthcare costs
whether CV- or other-related. Direct medical costs
included any cost incurred during the inpatient hospita-
lization associated with theC Ve v e n t ,i e .i n c l u d i n g
co-pay. If a CV event was the primary diagnosis in any
hospitalization (index or readmission), all costs from
that hospitalization were attributed to that CV event
and used in calculating total direct cost. Costs were
summed from the admit date to the discharge date for
hospitalizations. Costs were calculated based on allowed
health plan payments for medications and services and
expressed in 2006 US dollars ($). Costs were also
updated where necessary using the medical care compo-
nent of the US Consumer Price Index.
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Means, medians, and SDs for each cohort were calcu-
lated and reported for continuous variables. Distribu-
tions and frequencies were calculated for categorical
variables. Overall subject characteristics were reported
as well as for subject subsets (i.e., subjects with comor-
bid HTN, DYS, and/or DM).
Generalized linear models were used in main effects mul-
tivariable regression analyses of 1-year follow-up costs to
account for any remaining differences in variables used to
match subjects and non-normally-distributed payments
(common when using healthcare claims data). For the
CV-event group, the number of patients with a subsequent
CV event in the follow-up period was assessed, as well as
the number of subsequent CV events per person-year of
follow-up. Total direct medical costs and hospital LOS
associated with initial and subsequent CV events were
determined. The rate of subsequent CV events and costs
associated with initial and subsequent CV events are
reported overall as well for subsets with comorbid HTN,
DYS, or DM.
Because this was a non-controlled observational study, it
was expected that some degree of bias would exist among
study groups. Matching non-CV event subjects and adjust-
ments in multivariable analyses were used to control for
these biases. The following subject-specific covariates were
CV-event subjects (matched)
n=29,688
CV-event control subjects (matched)
n=29,688
Patients continuously enrolled for the entire pre-index period
n=120,160 (60.3%)
Patients with good data quality
n=77,460 (38.9%)
Patients >18 years of age
n=77,088 (38.7%)
Patients with index hospitalization stay <27 days
n=29,863 (15.0%)
Patients continuously enrolled for 360 days in the post-index period 
n=80,948 (40.7%)
Patients hospitalized for a CV event 
January 1, 2001 to June 30, 2005
n=198,961 (100%)
Patients without a CV-related claim in the pre-index period
n=30,000 (15.1%)
All eligible patients hospitalized for all CV events (pre-matched)
n= 29,863
Apply 1:1 Matching Criteria
Subjects with no diagnosis or procedure codes for a CV-event of interest
Matched for: exact age, gender, exact year of index date, and follow-up duration (in 60-day bands)
Final Study Cohorts
Figure 1 Diagram of study cohort identification procedure.
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date; gender; health plan type (consumer-directed health
care, HMO, indemnity, point of service [POS], PPO,
other/unknown); health plan payer type (commercial,
Medicaid, Medicare risk, self-insured, other/unknown);
geographic region at index date (Northeast, Midwest,
South, West); physician specialty at discharge from CV
event hospitalization (family practice/general practitioner
[FP/GP], internal medicine, cardiologist, other, unknown);
Dartmouth Manitoba version of Charlson Comorbidity
Index [CCI]; presence of DYS; presence of statin therapy
or other lipid-lowering therapy in the pre-index period;
presence of HTN; presence of type 2 DM; presence of
other medications to treat comorbidities of CV disease;
total health-care costs (i.e., payments by health plans to
providers) during the 12-month pre-index period. Only
main effects were considered; no interaction effects were
assessed in the models.
The excess cost of a CV event during follow-up was esti-
mated by comparing the total cost of care for CV-event
subjects to costs for control (non-CV-event) subjects dur-
ing follow-up. Resource utilization and costs were calcu-
lated for the first, second, and third years of follow-up. For
this analysis only, we required subjects to have at least 12-,
24-, or 36-months of post-index data, as needed. Utiliza-
tion and costs are reported by type of service and overall
in the following categories: medications (CV-related thera-
pies, all other medications); outpatient care (emergency
room visits, physician office visits, imaging tests, laboratory
procedures, all other outpatient services); inpatient care
(number of hospitalizations, hospital LOS in days).
Along with total health-care costs, CV-related costs
were also calculated. A claim was categorized as CV-
related if it was for diagnosis or procedure codes indicative
of disease (as listed above), for statin therapy, or other
lipid-lowering therapy, and for other concomitant CV
medications.
All analyses were conducted using SAS
® version 8.02
(SAS Institute Inc., Cary, NC, USA).
Results
Of the 198,961 patients identified with an index hospita-
lization for a CV event between January 1, 2001 and
June 30, 2005, the majority were excluded, predomi-
nantly for not fulfilling continuous enrolment require-
ments or for having a CV-related claim in the pre-index
period (Figure 1). A total of 29,688 individuals met cri-
teria to be CV-event subjects and were matched with
29,688 control (non-CV-event) subjects. Among all
(matched) CV-event subjects, mean (SD) age was 55.5
(12.0) years and 37.2% (11,097) were female. Baseline
demographic and clinical characteristics for all matched
subjects, as well as matched CV-event subjects and
matched controls, are shown in Table 2.
Overall inpatient costs for index hospitalizations for
CV-event subjects were $16,981 per case (SD = $20,474;
median = $9996) with an average (SD) length of stay of
4.36 (3.06) days. These costs varied considerably by type
of CV event and ranged from a mean of $6699 for TIA/
other CVAs and $6910 for angina to $56,024 for CABG.
Mean LOS varied in a similar manner, from 2.71 days
per angina hospitalization to 9.23 days for CABG
(Table 3).
Mean overall costs for care in the first follow-up year
were $16,582 (SD = $34,425; median = $7408) (Table 4).
Overall mean follow-up costs increased to $26,644 at 2-
year follow-up and to $34,131 at 3-year follow-up.
As expected, analysis of the matched cohort of CV-
event versus control subjects found that mean total
costs for year-1 follow-up healthcare were much higher
for CV-event subjects ($16,582) than for those without
CV events ($2790) (Table 4), an excess of $13,792 over
matched controls’ mean cost. Mean total healthcare
costs in the year prior to the index CV event ($5124)
were lower than in the year following the CV event, but
were still much higher than year-1 costs for matched
control subjects without a CV event (Table 4). The gap
between costs for CV-event subjects and matched con-
trol subjects was even larger when mean total costs
were compared at 2-year ($26,644 vs. $5782 per subject,
respectively) and 3-year follow-up ($34,131 versus $8117
per subject, respectively) (Table 4, Figure 2). The differ-
ence in average costs between CV-event and matched-
control subjects was $20,862 after 2 years and $26,014
after 3 years of follow-up.
In the multivariable model of main effects adjusting
for demographic and clinical differences between sub-
jects, presence of a CV event was the strongest predictor
of total 1-year follow-up costs (P <0.0001) (Table 5).
Age, hypertension, hyperlipidemia, and diabetes, were
also statistically significant predictors of increased costs.
Payer type and geographic region were related to
increased cost of CV events in some instances, but plan
type and physician specialty had no significant associa-
tion with follow-up costs.
Among the overall CV-event cohort, 4805 (16.1%)
patients experienced at least one subsequent CV event
leading to hospitalization. The overall mean hospital
length of stay was 4.85 days, with CABG having the
greatest LOS at 8.87 days per event. The overall mean
hospitalization cost for the subsequent CV event was
only slightly higher than the overall mean cost per index
event ($17,709 vs. $16,981, respectively; data not
shown). Differences in mean costs were generally within
$3000 or less of each other, with the largest absolute
differences occurring for CABG ($46,236 recurrent vs.
$56,024 initial) and other CV procedures ($19,023
recurrent vs. $26,254 initial).
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In this retrospective claims database analysis, we docu-
ment the high costs for CV events and follow-up care
(for 1 to 3 years) in a commercially-insured US popula-
tion. In particular, mean healthcare costs among CV-
event subjects were substantially higher in post-index
years compared to control subjects. Among CV-event
subjects, initial hospitalization costs varied widely by
type of CV event ranging from $6,699 for a TIA to
$56,024 for a CABG.
The 1-year follow-up costs for CV events were almost
as high as the initial hospitalization costs, and were
much higher at 2- and 3-year follow-up. These data are
consistent with previous evidence showing that persons
with CVD incur significantly greater direct medical
costs than persons without CVD, with the annual
Table 3 Unadjusted costs of index hospitalization among all CV event subjects
Overall CABG Other CV
Procedures
MI Heart
Failure
Angina Other Ischemic
Heart Disease
Stroke TIA/
other
CVAs
PVD
Total patients n 29,688 1894 8581 9151 2230 1650 11,224 2600 2317 164
Cost of index
hospitalization mean
(SD)
$16,981
($20,474)
$56,024
($33,207)
$26,254
($21,089)
$25,022
($24,857)
$12,052
($15,152)
$6910
($7,585)
$15,278
($17,974)
$12,365
($12,667)
$6699
($6,447)
$16,269
($19,831)
LOS, days mean (SD) 4.36
(3.06)
9.23
(3.65)
4.08 (2.41) 4.68
(3.00)
5.59
(3.59)
2.71
(1.40)
3.82 (2.67) 5.44
(3.37)
3.78
(2.83)
6.99
(5.37)
CABG = coronary artery bypass graft; MI = myocardial infarction; TIA = transient ischemic attack; CVA = cerebrovascular accidents; PVD = peripheral vascular
disease; LOS = length of stay.
Patients could be classified into >1 event type.
Table 2 Baseline demographic and clinical characteristics
Demographic and Clinical Characteristics CV-Event Patients
(matched)
CV-Event Control Patients
(matched)
P-value
Total Subjects 29,688 29,688
Age, mean (years) 55.5 55.4 0.5474
Age groups, % 0.9963
18-34 2.55 2.53
35-44 11.46 11.55
45-54 34.72 34.74
55-64 38.05 37.94
65+ 13.22 13.23
Gender, % 1.00
Female 37.15 37.15
Payer type at index, % <0.0001
Commercial Plan 74.75 74.35
Medicare 1.10 0.50
Medicaid Risk 13.87 13.41
Self-Insured 4.92 5.88
Unknown 5.35 5.85
Geographic Region at index, % <0.0001
Northeast 19.26 22.31
Midwest 42.58 41.34
South 32.18 27.59
West 5.98 8.76
Duration of follow-up, mean (days) 696 696 0.7103
CCI, mean 0.56 0.27 <0.0001
Pre-index presence of DYS, % 30.12 22.08 <0.0001
Pre-index presence of HTN, % 39.01 22.01 <0.0001
Pre-index presence of DM, % 18.39 7.06 <0.0001
Pre-index 12-month total healthcare costs (mean), $ in 1000s $5124 $2652 <0.0001
CV = cardiovascular; CCI = Charlson Comorbidity index; DYS = dyslipidemia; HTN = hypertension; DM = diabetes mellitus.
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Page 6 of 10lifetime medical cost of treating CVD patients estimated
to be 3.4 times greater than for patients without CVD
[2,3].
O u rd a t aw e r ec o n s i s t e n tw i t hp r e v i o u se v i d e n c et h a t
has shown that the costs of CV events and associated fol-
low-up care in patients with HTN, DM, and DYS is
higher than the overall mean healthcare costs for CV-
event subjects without a co-morbidity [4-9]. Previous
analyses using the current database have shown that dia-
betic patients hospitalized for a cardiovascular event
incur higher costs for overall cardiovascular care and for
most types of individual cardiovascular events than their
non-diabetic counterparts [10]. Other analyses have
demonstrated that DM patients with cardiovascular co-
morbidity had significantly higher total healthcare costs
(38.9%; $12,550 vs. $9031), total Emergency Room (ER/
hospitalization costs (239.8%; $4845 vs. $1426), total out-
patient costs (35.3%; $3956 vs. $2925), and total prescrip-
tion drug costs (15.1%; $4686 vs. $4071) compared to
DM patients without cardiovascular co-morbidity [11].
Similarly, uncontrolled HTN is estimated to result in
39,702 CV events, 8374 CVD deaths, and $964 million in
annual direct medical expenditures in the US [12].
The global burden of CVD is increasing and is
expected to surpass infectious disease to become the
world’s leading cause of death and disability by the year
2020 [7]. The American Heart Association estimated the
total annual direct medical expenditures for patients with
CVD or stroke to be $131.3 billion in 2008 [13], and
recent analyses indicate that the actual economic burden
to be substantially higher than this [14].
Because of the growing demand for scarce healthcare
resources and the introduction of new, more expensive
technologies, difficult choices must be made among
competing therapeutic options and priorities [15,16].
Economic evaluation provides a means of rationally
informing these choices so that the result is an efficient
allocation of resources.
Accurate estimates of medical event costs are integral
for pharmacoeconomic modeling. However, it is nearly
impossible to accurately determine whether the clinical
advantages of a novel CV therapy are likely to result in
net cost-savings, for example due to reductions in
events, procedures or hospital length of stay, if occur-
rence rates and costs for specific CV events are not
known.
Table 4 Unadjusted costs for CV-event and matched control groups at 1-, 2-, and 3-year follow-up
Pre-Index Year 1 Years 1-2 Years 1-3
CV-Event
(n = 29,688)
CV-Event
(n = 29,688)
Control
(n = 29,688)
CV-Event
(n = 11,620)
Control
(n = 11,620)
CV-Event
(n = 3853)
Control
(n = 3853)
mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)
Resources Used median median median median median median median
CV-related
medications
$285 ($619) $813 ($1051) $180 ($493) $1676 ($1885) $394 ($958) $2530 ($2579) $662 ($1426)
$0 $471 $0 $1,121 $0 $1757 $0
All other
medications
$1135 ($4511) $1917 ($5936) $588 ($2423) $3687 ($10,272) $1273 ($4558) $5064 ($11,456) $1921 ($4932)
$149 $756 $20 $1,487 $139 $2166 $399
Emergency room $186 ($728) $390 ($1593) $68 ($447) $704 ($2086) $134 ($601) $1113 ($2734) $217 ($735)
$0 $0 $0 $0 $0 $96 $0
Physician office
visit
$637 ($2442) $1,248 ($3409) $398 ($907) $2145 ($6820) $849 ($1550) $2726 ($5710) $1208 ($2016)
$301 $725 $178 $1335 $459 $1836 $719
Imaging tests $397 ($1624) $858 ($2130) $232 ($1252) $1384 ($3125) $435 ($1680) $1616 ($2600) $551 ($1627)
$12 $193 $0 $679 $40 $903 $91
Laboratory
procedures
$187 ($628) $356 ($1119) $118 ($335) $630 ($1810) $256 ($607) $783 ($1541) $357 ($835)
$38 $144 $3 $317 $96 $451 $169
All other
outpatient
services
$1384 ($5070) $3692 ($9745) $781 ($3125) $6051 ($14,075) $1640 ($6722) $7826 ($17,797) $2214 ($5018)
$127 $1321 $22 $2644 $239 $3600 $594
Hospitalization $912 ($7120) $7308 ($27,680) $424 ($4258) $10,367 ($35,024) $800 ($5082) $12,473 ($34,671) $986 ($5488)
$0 $0 $0 $0 $0 $0 $0
Total Care $5124 ($13,465) $16,582 ($34,425) $2790 ($7837) $26,644 ($48,086) $5782 ($12,807) $34,131 ($51,331) $8117 ($12,634)
$1917 $7408 $856 $13,761 $2622 $19,194 $4528
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tive in nature, it is important to highlight some limita-
tions in the interpretation of our findings. Accurate
assessment of costs and resource utilization is heavily
dependent on the correct allocation of diagnosis, proce-
dure, and medication codes. In order that errors in the
assignment of codes were minimal, all patient medical
histories were subject to stringent data checks. In addi-
t i o n ,o n l yh e a l t h - c a r ep l a n sthat provided information
for all members were included in the database, ensuring
complete data capture and representative samples. In
addition, as the costs report e dh e r ea r ed e r i v e df r o m
commercial managed care claims data, results may not
be generalizable to other populations.
The multivariable model used was adjusted for the pre-
sence of DYS, HTN and DM. It is possible that inclusion
of other co-morbidities may have affected the results of
these analyses., Patients who died were included in our
analyses as completed cases; however, patients who were
lost to follow-up were excluded. Consequently, mean
costs may have been biased towards patients who died
soon after hospitalization. These patients may have
incurred higher costs, as they may have been sicker and
required more expensive treatment. Although our data
precludes confirmation of this presumption, the esti-
mates provided from our analysis remain a reasonable
contemporary assessment of the costs within the limita-
tions of our data set.
The findings from this study provide important esti-
mates for pharmacoeconomic modeling of cardiovascu-
lar events, and are expected to benefit multiple
stakeholders, including patients and policy-makers
deciding how to most efficiently allocate healthcare
resources.
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